(VRNS) Varonis Systems - Overview
Stock: Data Classification, Exposure Remediation, Threat Detection, Data Security
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 37.4% |
| Relative Tail Risk | -12.7% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.59 |
| Alpha | -61.59 |
| Character TTM | |
|---|---|
| Beta | 0.842 |
| Beta Downside | 0.629 |
| Drawdowns 3y | |
|---|---|
| Max DD | 64.92% |
| CAGR/Max DD | -0.10 |
Description: VRNS Varonis Systems January 09, 2026
Varonis Systems (NASDAQ: VRNS) develops AI-driven software that continuously discovers, classifies, and protects both structured and unstructured data across on-premises, SaaS, and cloud environments, targeting exposures and advanced threats.
The platform secures data in major public clouds (AWS, Azure, Google Cloud) and popular SaaS applications such as Microsoft 365, Salesforce, Snowflake, ServiceNow, Google Drive, and Box, while also supporting Windows, NAS, and Linux storage on-premises.
Its Managed Data Detection and Response (MDDR) service extends the core technology with a 24/7 threat-hunting operation that investigates and mitigates data-centric attacks for customers in financial services, healthcare, manufacturing, technology, insurance, energy & utilities, consumer & retail, education, construction, and the public sector.
Key metrics from the most recent fiscal year show revenue of $590 million, a 23 % year-over-year increase, and an ARR growth rate of ≈ 30 % driven by strong adoption of the cloud-security module; the company maintains a gross margin of ≈ 84 %, reflecting the high-margin nature of software licensing and subscription revenue.
Sector-wide, the data-security market is projected to expand at a CAGR of 12 % through 2028, fueled by rising regulatory scrutiny (e.g., GDPR, CCPA) and the acceleration of digital transformation that pushes more critical data into hybrid environments.
For a deeper, data-rich perspective on Varonis’s valuation and risk profile, consider exploring the ValueRay analytics platform.
Piotroski VR‑10 (Strict, 0-10) 4.5
| Net Income: -114.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA 1.68 > 1.0 |
| NWC/Revenue: 70.56% < 20% (prev 87.90%; Δ -17.34% < -1%) |
| CFO/TA 0.09 > 3% & CFO 147.0m > Net Income -114.5m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.81 > 1.5 & < 3 |
| Outstanding Shares: last quarter (113.3m) vs 12m ago 0.88% < -2% |
| Gross Margin: 80.04% > 18% (prev 0.84%; Δ 7920 % > 0.5%) |
| Asset Turnover: 38.21% > 50% (prev 35.93%; Δ 2.28% > 0%) |
| Interest Coverage Ratio: -12.22 > 6 (EBITDA TTM -90.9m / Interest Expense TTM 8.30m) |
Altman Z'' -1.20
| A: 0.26 (Total Current Assets 961.4m - Total Current Liabilities 531.9m) / Total Assets 1.67b |
| B: -0.51 (Retained Earnings -841.7m / Total Assets 1.67b) |
| C: -0.06 (EBIT TTM -101.5m / Avg Total Assets 1.59b) |
| D: -0.78 (Book Value of Equity -823.2m / Total Liabilities 1.06b) |
| Altman-Z'' Score: -1.20 = CCC |
Beneish M -2.71
| DSRI: 1.07 (Receivables 142.6m/119.2m, Revenue 608.7m/546.5m) |
| GMI: 1.05 (GM 80.04% / 84.06%) |
| AQI: 1.50 (AQ_t 0.37 / AQ_t-1 0.24) |
| SGI: 1.11 (Revenue 608.7m / 546.5m) |
| TATA: -0.16 (NI -114.5m - CFO 147.0m) / TA 1.67b) |
| Beneish M-Score: -2.71 (Cap -4..+1) = A |
What is the price of VRNS shares?
Over the past week, the price has changed by -24.10%, over one month by -31.98%, over three months by -33.60% and over the past year by -43.39%.
Is VRNS a buy, sell or hold?
- StrongBuy: 10
- Buy: 4
- Hold: 6
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the VRNS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 48.2 | 112.6% |
| Analysts Target Price | 48.2 | 112.6% |
| ValueRay Target Price | 22.1 | -2.3% |
VRNS Fundamental Data Overview February 04, 2026
P/S = 5.6656
P/B = 5.9588
P/EG = 6.8414
Revenue TTM = 608.7m USD
EBIT TTM = -101.5m USD
EBITDA TTM = -90.9m USD
Long Term Debt = 451.8m USD (from longTermDebt, last quarter)
Short Term Debt = 8.99m USD (from shortTermDebt, last quarter)
Debt = 520.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 363.3m USD (from netDebt column, last quarter)
Enterprise Value = 3.26b USD (3.45b + Debt 520.7m - CCE 707.9m)
Interest Coverage Ratio = -12.22 (Ebit TTM -101.5m / Interest Expense TTM 8.30m)
EV/FCF = 24.34x (Enterprise Value 3.26b / FCF TTM 134.0m)
FCF Yield = 4.11% (FCF TTM 134.0m / Enterprise Value 3.26b)
FCF Margin = 22.01% (FCF TTM 134.0m / Revenue TTM 608.7m)
Net Margin = -18.82% (Net Income TTM -114.5m / Revenue TTM 608.7m)
Gross Margin = 80.04% ((Revenue TTM 608.7m - Cost of Revenue TTM 121.5m) / Revenue TTM)
Gross Margin QoQ = 78.25% (prev 79.46%)
Tobins Q-Ratio = 1.96 (Enterprise Value 3.26b / Total Assets 1.67b)
Interest Expense / Debt = 1.59% (Interest Expense 8.30m / Debt 520.7m)
Taxrate = 21.0% (US default 21%)
NOPAT = -80.2m (EBIT -101.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.81 (Total Current Assets 961.4m / Total Current Liabilities 531.9m)
Debt / Equity = 0.86 (Debt 520.7m / totalStockholderEquity, last quarter 604.8m)
Debt / EBITDA = -4.00 (negative EBITDA) (Net Debt 363.3m / EBITDA -90.9m)
Debt / FCF = 2.71 (Net Debt 363.3m / FCF TTM 134.0m)
Total Stockholder Equity = 442.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -7.19% (Net Income -114.5m / Total Assets 1.67b)
RoE = -25.89% (Net Income TTM -114.5m / Total Stockholder Equity 442.4m)
RoCE = -11.35% (EBIT -101.5m / Capital Employed (Equity 442.4m + L.T.Debt 451.8m))
RoIC = -7.41% (negative operating profit) (NOPAT -80.2m / Invested Capital 1.08b)
WACC = 8.00% (E(3.45b)/V(3.97b) * Re(9.02%) + D(520.7m)/V(3.97b) * Rd(1.59%) * (1-Tc(0.21)))
Discount Rate = 9.02% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.93%
[DCF Debug] Terminal Value 81.25% ; FCFF base≈119.1m ; Y1≈147.0m ; Y5≈250.3m
Fair Price DCF = 32.78 (EV 4.23b - Net Debt 363.3m = Equity 3.86b / Shares 117.9m; r=8.00% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 13.14 | EPS CAGR: -23.01% | SUE: 0.59 | # QB: 0
Revenue Correlation: 70.25 | Revenue CAGR: 6.73% | SUE: -0.38 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.05 | Chg30d=+0.004 | Revisions Net=+1 | Analysts=16
EPS next Year (2026-12-31): EPS=0.34 | Chg30d=+0.006 | Revisions Net=+1 | Growth EPS=+168.9% | Growth Revenue=+16.2%